Nurix Therapeutics, Inc. Common stock
NRIXNurix Therapeutics, Inc. is a biotechnology company focused on developing innovative small molecule therapies that modulate the ubiquitin-proteasome system to treat cancer, autoimmune, and inflammatory diseases. The company's approach involves targeting protein degradation pathways to selectively manipulate cellular processes and restore healthy function. Founded to advance precision medicine, Nurix leverages its expertise in drug discovery to develop targeted therapeutics with potential for broad clinical applications.
Company News
Nurix Therapeutics announced a strategic partnership with Roche to co-develop and co-commercialize bexobrutideg, a BTK degrader for B-cell blood cancers. Nurix will receive $700 million upfront with potential milestone payments up to $2.3 billion total. The companies will share development costs (40/60 split) and equally split U.S. commercializat...
Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including ...
Nurix Therapeutics presented preclinical data at AACR 2026 demonstrating advances across its oncology pipeline, including pan-mutant BRAF degrader NRX-0305, CBL-B inhibitor NX-1607, and AURKA degrader NRX-4972. The data showcase the potential of targeted protein degradation therapies to overcome limitations of traditional inhibitors, with NRX-030...
The follicular lymphoma drug development pipeline is experiencing significant growth with 45+ companies actively developing 50+ pipeline therapies. Major pharmaceutical players including AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, and others are advancing promising candidates through various clinical trial phases, with approximately 5...
Nurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million (down from $18.5 million YoY) and net loss of $87.2 million. The company is advancing its registrational program for bexobrutideg with Phase 2 DAYBreak CLL-201 enrollment ongoing for accelerated approval in relapsed/refractory CLL, and plans to initiate Phase 3 DAY...
